Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab, suggesting it would reduce annualized fracture rates [5]. - It is alleged that while making these positive statements, Mereo BioPharma concealed material adverse facts about the Phase 3 programs, which did not meet their primary endpoints [6]. - The misleading information led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true details were revealed [6]. Group 2: Participation Information - Investors who purchased Mereo ADSs during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7]. - A lead plaintiff must be appointed by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the potential of setrusumab and its study protocols, impacting investors who purchased stock between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false and/or misleading statements about setrusumab's ability to increase bone density and its correlation with fracture rates, which were misrepresented to investors [5]. - Investors who purchased common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of BlackRock TCP Capital Corp. securities, alleging that the company made materially false and misleading statements regarding its business operations and financial health during the specified Class Period from November 6, 2024, to January 23, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that BlackRock TCP's investments were not being timely and appropriately valued, leading to understated unrealized losses and overstated net asset value (NAV) [5]. - Defendants allegedly failed to disclose material adverse facts about BlackRock TCP's business, including ineffective portfolio restructuring efforts [5]. - The lawsuit asserts that the misleading statements made by the defendants resulted in damages to investors when the true details became public [5]. Group 2: Participation Information - Investors who purchased BlackRock TCP securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - Founding partner Laurence Rosen has received recognition as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Beyond Meat, Inc. securities of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the specified Class Period [1][5]. Group 1: Class Action Details - The Class Period for the lawsuit is from February 27, 2025, to November 11, 2025, inclusive [1]. - Investors who purchased Beyond Meat securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 24, 2026 [3]. Group 2: Allegations Against Beyond Meat - The lawsuit alleges that Beyond Meat made materially false and misleading statements regarding the book value of certain long-lived assets, which exceeded their fair value, indicating a likely need for a material, non-cash impairment charge [5]. - It is claimed that these misstatements could impair Beyond Meat's ability to file periodic reports with the Securities and Exchange Commission in a timely manner [5]. - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements made by the defendants [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased America's Car-Mart securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to America's Car-Mart [2]. Group 2: Company Performance and Market Reaction - On September 4, 2025, America's Car-Mart reported a first-quarter loss of $0.69 per share, compared to a net loss of $0.15 per share in the same period the previous year, leading to an 18.2% drop in stock price on that day [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Kyndryl Holdings, Inc. securities for the period between August 7, 2024, and February 9, 2026, due to alleged misleading statements and financial misstatements [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Kyndryl's financial statements during the Class Period were materially misstated and that the company lacked adequate internal controls [5]. - It is alleged that Kyndryl would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025, which contributed to the misleading nature of the defendants' statements regarding the company's business and operations [5]. Group 2: Participation Information - Investors who purchased Kyndryl securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Plug Power Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and financial statements [1][5]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Plug Power securities between January 17, 2025, and November 13, 2025 [1]. - Investors who purchased securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by April 3, 2026, to represent other class members in the litigation [3]. Group 2: Allegations Against Plug Power - The lawsuit alleges that defendants made false and misleading statements regarding the availability of funds from the U.S. Department of Energy's Loan and the construction of hydrogen production facilities [5]. - It is claimed that Plug Power was likely to pivot towards less ambitious projects with lower commercial potential, contradicting earlier public statements [5]. - The lawsuit asserts that these misleading statements resulted in investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CoreWeave, Inc. (NASDAQ: CRWV) between March 28, 2025 and December 15, 2025, both dates inclusive (the “Class Period”), of the important March 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased CoreWeave securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of securities of Richtech Robotics Inc. for the period between January 27, 2026, and January 29, 2026, due to alleged false statements made by the company regarding its relationship with Microsoft [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Richtech Robotics falsely stated it had a collaborative relationship with Microsoft, which was not true, leading to misleading information about the company's business and prospects [5]. - Investors who purchased Richtech Robotics securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly. A lead plaintiff must be appointed by April 3, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit on behalf of shareholders of uniQure N.V. (NASDAQ: QURE) due to allegations of misleading investors regarding the company's business operations and the approval status of its pivotal study for a drug candidate targeting Huntington's Disease [1] Group 1: Allegations Against uniQure N.V. - The lawsuit claims that uniQure misrepresented the approval status of its pivotal study by the U.S. Food and Drug Administration (FDA) [1] - It is alleged that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [1] - The lawsuit asserts that the statements made by uniQure regarding its business, operations, and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [1] Group 2: Class Action Participation - Shareholders who wish to serve as lead plaintiffs must file their motions by April 13, 2026 [1] - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members if they choose [1] - All legal representation is provided on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [1]